Literature DB >> 13638638

Phenylbutazone and its derivatives with special reference to G.27202.

F D HART, D BURLEY.   

Abstract

Entities:  

Keywords:  PHENYLBUTAZONE/related compounds

Mesh:

Substances:

Year:  1959        PMID: 13638638      PMCID: PMC1993074          DOI: 10.1136/bmj.1.5129.1087

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  7 in total

1.  Value of uricosuric agents and in particular of G. 28 315 in gout.

Authors:  G D KERSLEY; E R COOK; D C TOVEY
Journal:  Ann Rheum Dis       Date:  1958-09       Impact factor: 19.103

2.  Phenylbutazone metabolites: antirheumatic, sodium-retaining and uricosuric effects in man.

Authors:  T F YU; J J BURNS; B C PATON; A B GUTMAN; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1958-05       Impact factor: 4.030

3.  The present status of phenylbutazone therapy in rheumatic disease.

Authors:  R M MASON; R R HAYTER
Journal:  Practitioner       Date:  1958-07

4.  Evaluation of uricosuric agents in chronic gout.

Authors:  M A OGRYZLO; J HARRISON
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

5.  RICKARD CHRISTOPHERS, 80.

Authors: 
Journal:  Br Med J       Date:  1953-11-28

6.  The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material.

Authors:  J J BURNS; R K ROSE; T CHENKIN; A GOLDMAN; A SCHULERT; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1953-11       Impact factor: 4.030

7.  The status of phenylbutazone (butazolidin) in the treatment of rheumatic disorders.

Authors:  W GRAHAM
Journal:  Can Med Assoc J       Date:  1958-10-15       Impact factor: 8.262

  7 in total
  8 in total

1.  TRIAL OF NIFENAZONE ("THYLIN").

Authors:  F D HART; P L BOARDMAN
Journal:  Br Med J       Date:  1964-06-13

2.  Chronic duodenal obstruction: a mechano-vascular etiology of pancreatitis. II. Experimental observations.

Authors:  A PAULINO-NETTO; D A DREILING
Journal:  Am J Dig Dis       Date:  1960-12

3.  A controlled trial of phenylbutazone, oxyphenbutazone, and a placebo in the treatment of rheumatoid arthritis.

Authors:  R I MEANOCK; E LEWIS-FANING
Journal:  Ann Rheum Dis       Date:  1961-06       Impact factor: 19.103

4.  Pyrazolidines in the treatment of gout.

Authors:  W C Kuzell
Journal:  Can Med Assoc J       Date:  1968-11-30       Impact factor: 8.262

5.  A preliminary report of the anti-inflammatory effect of oxyphenbutazone (G27202) in postoperative obstetrical and gynecological practice.

Authors:  W D FRASER; P J BEARDALL; G B MAUGHAN
Journal:  Can Med Assoc J       Date:  1961-08-05       Impact factor: 8.262

6.  Hydroxy-phenylbutazone (Tanderil) in the treatment of ocular disease. A preliminary survey.

Authors:  L E WERNER
Journal:  Br J Ophthalmol       Date:  1960-12       Impact factor: 4.638

7.  Effects of oxyphenbutazone (tandearil) on plasma seromucoids. II. In postoperative inflammation.

Authors:  R BARCELO; C LEBLANC; P RIOPEL; L P LEGRESLEY
Journal:  Can Med Assoc J       Date:  1963-03-23       Impact factor: 8.262

8.  Effects of oxyphenbutazone (Tandearil) on plasma seromucoids. I. In experimental inflammation.

Authors:  R BARCELO; P RIOPEL; L P LEGRESLEY
Journal:  Can Med Assoc J       Date:  1963-03-16       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.